National Cancer Institute (NCI)s

National Cancer Institute (NCI)

428 Protocols (227 Active Accrual of new subjects, 201 Follow-up of previously enrolled subjects)

 002539-C:

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

 002394-C:

Longitudinal Study of Individuals and Families with Aberrations in DDX41 or Similar Cancer Predisposition Variants

 002389-C:

A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2)

 002354-C:

Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors

 002268-C:

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

 002095-C:

Phase II Trial of Alpelisib with iNOS Inhibitor and Nab-paclitaxel in Patients with HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)

 002090-C:

ComboMATCH Treatment Trial N5: Randomized Trial of Neratinib, a Pan-ErbB Inhibitor alone or in combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and other Solid Tumors

 002088-C:

A Phase I Study of Autologous T Cells Transduced with Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, and other Hematologic Malignancies

 002060-C:

ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors

 002058-C:

A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-related Inhibitor M1774

 002041-C:

Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)

 002029-C:

A Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia

 002021-C:

Phase 1 Study with Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants with Mesothelin-Expressing Solid Tumors Including Mesothelioma

 001969-C:

Open-Label Study of Zopapogene Imadenovec Retreatment and Vector Shedding Evaluation in Adult Patients with Recurrent Respiratory Papillomatosis

 001961-C:

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

 001951-C:

Natural History Study of Kaposi Sarcoma

 001924-C:

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

 001891-C:

An Exploratory Study Using a Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

 001863-C:

Screening Protocol for Clinical Trial Eligibility

 001859-C:

A Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

 001844-C:

A Phase 1/2, Open-Label, Basket Study to Assess the Safety, Tolerability, and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors

 001842-C:

Phase I Trial of rhIL-15 plus Dinutuximab plus Irinotecan/Temozolomide for Children and Young Adults with Relapsed/Refractory Neuroblastoma

 001837-C:

A Phase I Study to Establish the Feasibility of Enolen(TM) for the Local Delivery of Enzalutamide in Patients with Prostate Cancer

 001827-C:

Phase 3, Multicenter, Randomized, Open-Label Study to Assess the Efficacy and Safety Of the Lifileucel (LN-144), Autologous Tumor-Infiltrating Lymphocytes [TIL]) Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Partici

 001826-C:

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems using Pupillometry in Participants with Neurofibromatosis Type 1 (NF1)

 001811-C:

A Phase 1b/2 Study of Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma (RRMM)

 001796-C:

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

 001785-C:

Phase I Trial Integrating HLA-Haploidentical anti-CD19 CAR T cells with Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

 001776-C:

A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

 001774-C:

A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T cells (CCR4 CAR T cells) for CCR4 expressing T-cell Malignancies including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

 001771-C:

EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMATCH Treatment Trial)

 001770-C:

Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers

 001756-C:

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

 001750-C:

A Prospective Study of MRI-Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

 001749-C:

ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors

 001733-C:

A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

 001732-C:

A Phase 1 Study of the Polymerase Theta (POL-Theta) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors

 001731-C:

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

 001730-C:

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination with Immunotherapy Vaccine PRGN-2009 in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

 001715-C:

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associ

 001713-C:

A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

 001711-C:

Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) with Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Parag

 001709-C:

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

 001696-C:

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

 001665-C:

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

 001662-C:

A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction with a Vaccine Directed Against these Antigens in Participants with Metastatic Cance

 001615-C:

Phase 2 Trial of Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity in Neurofibromatosis Type 1

 001601-C:

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

 001600-C:

Phase 2 Study Evaluating the Functional Status of the Adrenal Glands with [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

 001599-C:

Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for B-cell Leukemias

 001591-C:

Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors

 001587-C:

A Phase I Dose-escalation Study of Preoperative Radiation Therapy in Participants with Resectable Recurrent Abdominal Adrenocortical Carcinoma

 001570-C:

Phase I Dose Escalation Study of FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory Rhabdomyosarcoma

 001569-C:

A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

 001564-C:

A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 alone or in Combination with PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

 001563-C:

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

 001559-C:

A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

 001557-C:

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

 001556-C:

Phase II Trial of Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) without Testosterone Lowering Therapy

 001552-C:

Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors

 001548-C:

A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination with Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects with Biliary Tract Carcinoma (BTC)

 001547-C:

A First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

 001542-C:

Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants with Germline RUNX1 Deficiency

 001538-C:

A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

 001537-C:

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

 001535-C:

A Phase II Study of Sacituzumab Govitecan with or without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcin

 001534-C:

Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN Amplifications

 001533-C:

A Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

 001525-C:

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

 001523-C:

A Phase II Study of Lurbinectedin with or without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

 001516-C:

Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer

 001109-C:

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

 001099-C:

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that

 001056-C:

Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

 000975-C:

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

 000958-C:

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

 000860-C:

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

 000792-C:

A Pilot Trial to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following CAR T-cell Induced Remission in Pediatric Patients with B Lineage Acute Lymphoblastic Leukemia

 000726-C:

A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

 000678-C:

Rare Tumors and Cancer Predisposition in Individuals and Families

 000666-C:

A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

 000661-C:

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

 000657-C:

Acceptance and Commitment Therapy for Caregivers of Children with a RASopathy: An Internal Pilot Feasibility Study and Follow-up Phase III Randomized Controlled Trial

 000643-C:

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

 000631-C:

Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell Therapy

 000628-C:

A Study of Prospective Monitoring of Subjects with Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL

 000613-C:

Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St

 000611-C:

A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer

 000509-C:

An Open Label, Multi-Center Roll-Over Study to Assess Long-Term Safety in Patients Who are Ongoing or Have Completed a Prior Global Novartis or GSK Sponsored Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Study and are Judged by the Investigator to B

 000491-C:

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

 000489-C:

Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies

 000481-C:

Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

 000478-C:

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis with Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living with HIV (PLWH

 000475-C:

Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)

 000473-C:

A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma

 000404-C:

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

 000359-C:

Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies

 000354-C:

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

 000337-C:

Natural History Study of KSHV-Associated Multicentric Castleman's Disease

 000324-C:

Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Next 100 Protocols